期刊
CLINICAL CANCER RESEARCH
卷 18, 期 15, 页码 4013-4018出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-11-1402
关键词
-
类别
资金
- Leukemia and Lymphoma Society
- National Cancer Institute [P50 CA140158, PO1 CA95426, PO1 CA81534, 1K12 CA133250]
- Harry Mangurian Foundation
- D. Warren Brown Foundation
The advent of targeted therapy, specifically to the B-cell receptor (BCR), has changed the convention for the treatment of chronic lymphocytic leukemia (CLL). The phosphoinositide 3-kinase (PI3K) pathway, activated upstream by the BCR, receptor tyrosine kinases, and cytokine receptors, has been a potential target for a multitude of cancers, but until the recent introduction of isoform-specific inhibitors has not been widely used. In this review, we focus on describing the intricate upstream and downstream signaling, leading to cell survival mediated by PI3K in B cells with a specific focus on the impact and importance of the p110 delta isoform (which is localized to hematopoietic cells and regulates distinct cellular functions in B cells). In addition, the clinical advances from targeting p110 delta are described, with a focus on clinical outcome, toxicities, and rational combination therapies. The experiences with p110 delta in CLL have led to a more fundamental understanding of CLL signaling defects and may be predictive of other BCR-directed therapeutics. Clin Cancer Res; 18(15); 4013-8. (C)2012 AACR.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据